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While preparing this paper, I pondered what a scientist’s perspective should be.
Although I no longer work at the bench, I am closely involved in the
continuum of scientific research through technology to its application, and
especially in its transfer to developing countries. I will briefly consider six
aspects of science and end with a challenge: to come up with new proposals for
action. How can people in the over-stocked grocery stores be made to change
their attitudes to the new science and technology so that its benefits will accrue
to those who are most deserving—the disadvantaged millions in the developing
world?
SCIENCE AND PUBLIC POLICY
The modern world-view includes science as a central element. Indeed, almost
everyone demands scientific certainty, e.g. with regard to global warming, ozone
depletion, and biotechnology’s safety. Yet, many people do not hold scientific
views as to the origins of life and other areas that affect our daily lives. On one
hand, we “demand” scientific certainty, yet on the other hand we reject
scientific information, data, and conclusions. How does that paradox continue
to exist? Evidently, it persists because we all seem to have a high degree of
tolerance for contradictions, and because we select the areas in which we
demand scientific certainty to suit our impulses. Consequently, it seems
impossible for policy makers to formulate science-based policies.
Paradoxically, although Europeans reject biotechnology that affects their
food, they accept it in the pharmaceutical area. But in developing countries
the most pressing health hazard is malnutrition. Diseases related to under-
nourishment kill approximately 40,000 children per day. So what is a luxury
for Europeans—safer food with fewer pesticide residues, more plentiful and
less expensive—is a matter of survival for the majority of the inhabitants of
this Earth.
A sufficiency of high-quality food is the most basic element of good health.
By denying the transfer of this technology to developing countries through
restrictive policies so prevalent in Europe and elsewhere, we deny it also to
most of the people on this planet. But how does one cope with the environmen-
tal luddites and anti-industry activists who claim to be cleaning things up as
they misquote, misrepresent, misunderstand, or knowingly fail to read the
scientific literature? How should we respond to their propagation of error-
riddled rhetoric?
Even those who see biotechnology as a potential “problem” at least
acknowledge current population/resource problems. Yet many fail to recognize
that agricultural biotechnology is an imperative for the 2.4 billion people—40%
of the world’s population—who survive on less than $2 per day. They somehow
fail to see the potential for biotechnology to increase the productivity of
existing farmland and thereby reduce the impact of agriculture on the
environment, particularly in marginal and fragile ecosystems.
The critics of biotechnology, with their often-mindless comments, are doing
little to meet the developing world’s growing food needs, and, in a paradoxical
twist, this will result in even more environmental destruction. We need to make
it clear to people, such as Prince Charles, that the latest environmental
catastrophe in Mozambique will seem like a royal garden party compared to the
consequences of the social shifts and environmental degradation to come.
Denying the poor access to the benefits of biotechnology will deny them the
means of lifting themselves out of poverty. Denying technological advances is
surely one way of sustaining subsistence farming, which farmers do not want
and which does not help the environment.
I conclude from these few considerations and thoughts about science and
policy that the power of politics has trumped the truth of science. Therefore,
we must better communicate the science of biotechnology to the public and to
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politicians, and supplant current views with more-convincing arguments. In
view of the paradox outlined in the first paragraph of the section, if biotechnol-
ogy is to flourish, it will not be science-based arguments that will win the day.
SCIENCE AND COMMUNICATION
Scientists are notoriously inept at communicating their progress. This is partly
because science is often far removed from technology. Debating positive effects
of technology on society and on the consumer is a very different matter from
debating scientific advancements.
The general public’s views of science and technology are strongly influenced
by overall education level, science education, and cultural and social back-
ground, to name but a few criteria. Yet, divergent social groups are united by
common cultural values. Hence, for each group, communication strategies have
to be adapted to reflect the target audience’s cultural values. Communicating
values is vital for public acceptance of new technologies, and requires widening
of scientists’ perspectives. An attempt to widen perspectives of the impacts of
biotechnology is long past due. The goal, however, should not be to take the
issue away from environmentalists, but to ensure that more voices from more
constituencies are included in the discussion. Similarly, the “negative” debate
that industry has initiated in the context of organic agriculture—by pointing
out its limitations and dangers—is also a shortsighted approach that may
backfire.
We could attempt to characterize what different constituencies want, ranging
from farmers, commodity traders, food processors, consumers, environmental-
ists, and parents, to ministers of agriculture and heads of state (Table 1). It is
immediately apparent that the primary concerns of the various constituencies
are varied; hence, the messages to them must be different. Unfortunately, the
benefits of biotechnology have been conveyed to the public mainly by
scientists, whose talents, generally, do not include ability to communicate
effectively with lay people. Scientists must step outside the province of science
itself and abandon the belief that the truth is their bailiwick. The truth is,
nobody holds the truth.
Denying the poor access to the benefits of biotechnology
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Indeed, according to Roger Highfield, Science Editor of the Daily Telegraph,
“Many journalists would like you to think that they are seekers of the truth, but
I suspect that most are like me: curious gossips who like to show off by sharing
hot news with a big audience. That audience distrusts hacks as much as boffins.
But scientists could still learn from journalists. Journalists think carefully about
their audience and communicate accordingly.”
Farmers
TABLE 1.
Constituency Objectives/Goals Environmental/Development impact
High-yielding crops.
Less use of pesticides.
More-efficient use of inputs
(e.g. water, less transport).
High-quality products.
Decreased environmental impact.
Decreased secondary environmental
impact.
Productivity increases, value added,
healthier crops.
Plant
breeders
Better tools to make their work
more efficient.
Produce varieties that farmers
want and need.
Provide consumers with more
nutritious and all-round better
varieties.
Scientists in developed and developing
countries are now able to breed disease-
resistant, delayed-ripening, and hardier
varieties of crops.
Scientists To advance the frontiers of
science.
Discover and invent exciting
new technologies.
Benefit humankind.
Progress has been made, especially in
medicine, where disease diagnostics and
the production of substances that were
too expensive, such as insulin, are now
allowing people everywhere to lead
healthier lives.
Consumers Plenty of food with good and
increasingly better nutritional
value at relatively affordable
prices.
Biotechnology is making progress in that
direction possible—these are the most
exciting applications in the research and
development pipeline.
Company
(large and
small) CEOs
To sell what the consumer
needs in a way that ensures
that the company is sustainable
and profitable.
The economic potential of biotechnol-
ogy is enormous, for industrialized and
developing countries. It can be a win/
win proposition if we work together and
resist fear and distrust.
Government
officials
To ensure that the people of
their country equitably enjoy
the benefits of science and
technology.
To cast out the specter of
national poverty.
Biotechnology could help worldwide,
but only if the politicians are true
friends of the earth!
Parents To ensure that their children
can enjoy a better life on this
planet.
Biotechnology is helping already, in
agriculture, health, and the environ-
ment, to make the world a better place.
Scientists have failed to recognize that, for the lay public, biotechnology is
neither a technical nor a scientific matter. It is now part of the intricate
question of life itself. Hence, we must communicate this science and technology
in all-encompassing ways, invoking both traditional concepts of human culture
and economic development, and that of stewardship. Also, we must give
credence where it is due, including to organic agriculture. Contrary to what
activists and industry try to make the public believe, these are not two opposing
principles, but complementary ideals that should guide the creation of our
vision of the future and the steps we take to reach it.
Finally, communication has to begin at the school level. I believe it will take a
generation before biotechnology will be fully accepted.
SCIENCE AND INTELLECTUAL PROPERTY
It is evident that resolving the intellectual property (IP) aspects of this science
and technology is a rather multifaceted matter that daily increases in complex-
ity. The typical plant biotechnology company has a budget of millions of
dollars, sometimes into the hundreds of millions of dollars, for legal costs. But
scientists fail to see this as their concern—and indeed it is not—they would
rather avoid it and use the funds for research.
One of the fundamental problems is that the knowledge revolution enabled
by biotechnology has not been followed by a revolution in IP law. Once a sacred
right of the inventor, IP was stimulated both by metaphysical arguments over
ownership and by a desire to take practical measures to make inventions
quickly available. But times have changed. Consider Linux, the open-source
software to which everyone can contribute. It has seen the fastest software
evolution ever. At first Linux was developed as a response to Microsoft
Corporation’s domination of the operating-system world. Although driven by
this ideology, it makes good business sense too. The collaborative efforts of
programmers from around the world have created an impressive operating
system that is rapidly gaining market share. This “open-source,” group effort
has turned a fundamental business assumption on its head: people now see that
the value in software is not the software per se, but the productivity gains it
affords.
The same may apply to DNA and genes. One might well argue that we need
an open platform where everyone can contribute, where everyone benefits.
What a difference it would make if everyone could contribute to, and benefit
from, the productivity gains enabled through a better understanding and
knowledge of DNA and genes!
What proposals for action make sense? To make such an “open platform”
happen, a new definition of patents is needed to foster continued investment in
the science and technology and products. Perhaps a working group is needed to
try to come up with something new to save companies hundreds of millions of
dollars in legal fees. Yet, today we are bogged down in discussions about the
morality of ownership. We need less dogma and more common sense.
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BRINGING TECHNOLOGY TO THE CONSUMER
Food labeling is a typical aspect that may help or hinder the transfer of tech-
nology to the consumer. It can be a barrier, including a trade barrier. In the
context of the title of this paper, who will make the decisions for the world?
Wealthy, middle-aged, white, well fed, well clothed, well educated activists
in Seattle? Bureaucrats in Brussels? Let us remember that at least 60% of the
world’s consumers do not care about labeling—they simply want food on the
table. And of these, nearly 40% cannot read anyway. In any case, the majority
of foods sold to local consumers comes without packaging. Who is representing
the hungry and poor in such debates?
This gives us another criterion for our proposals for action: they must be
based on the world as it is rather than based on a romantic image of how
the world should be. We need to stop holding more than half the world’s
population hostage to poverty under the guise of debates about “safe” foods or
“safe trade.” In any case, safe food is not on offer; only safer food is on offer.
The “debates” are more about lifestyle choices in the industrialized, western
countries than they are about science-based analyses of new agricultural
technologies or of socio-economic realities affecting the 2.4 billion poorest of
our world. Further, the biotechnology debate is about technological acceptance
and not about science. This is something scientists find extremely difficult to
understand and even more so to accept. They prefer to indulge in the well
entrenched celebratory discourse because of the technological power that
biotechnology bestows.
SCIENCE AND BUSINESS
Whereas large companies spend huge amounts on legal fees, research per se is
being conducted more and more by smaller companies, often start-ups. Large
companies increasingly depend on small companies as sources of new products
and enabling technologies. Hence science—and research—is far from
moribund. There are many ways by which companies acquire research results.
They range from purchasing other companies to contract research to various
intermediate forms. The strategic alliance, one such intermediate form, is a
most critical part of technology-based industries. For example, 60% of Merck’s
products in the pipeline stem from alliances and partnering. This is nothing
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new. Similar shifts took place in other industries such as computers and
automobiles, and are still taking place in different forms in the chemical
industry.
Hence, in agricultural biotechnology, major shifts are likely, such as mergers
for consolidation. Some of these shifts have already been brought about by
those who oppose multinational companies. Other changes will be forced by
governments due to public opinion, which will significantly shape the decade
to come.
Some of these changes are due to the fact that agricultural biotechnology is
being deployed so incredibly quickly. Monsanto today earns perhaps as much as
$650 million from its biotechnology-based products. This has never been seen
in agriculture with any other product only five years after the first large-scale
commercial launch. In an area where change has been notoriously slow, how
come we are so surprised that the consumer has been unable to keep pace?
Naturally, scientists are as baffled as consumers are confused and as those in
developing countries are mystified, about the many corporate changes. And
more are to come.
SCIENCE AND INTERNATIONAL DEVELOPMENT
When considering international development, one invariably thinks of the
“Third” World, of small-scale farmers, of poverty, of hunger, of neo-colonialism,
of exploitation, of the Brazilian rain forest, of over-consumption, and of the
WTO, to name but a few. Biotechnology rarely enters the debate.
Changed attitudes are needed to introduce biotechnology in an appropriate
way in this area. And changing attitudes may result from two related ap-
proaches. First, for northern countries, biotechnology needs to be understood
better in terms of its significance for the lives of individuals in industrialized
countries and their children. One means of accomplishing this is to present the
issues in tangible terms, emphasizing actions that can be taken in industrialized
countries. Biotechnology needs to be understood as a global issue. Examples
abound primarily in the biodiversity area. The mold for penicillin, for example,
was discovered in North America, and a major Swiss pharmaceutical company
has found useful soil organisms in Scandinavia. Yellowstone Park, a center of
hot-spring activity, is a major source of heat-resistant microbes.
Care must be taken to present biotechnology as a concept. This message can
be enhanced by the second approach: the advancement of environmental
stewardship. Individuals, even those with limited contact with natural
environments on a daily basis, seem to understand the need to conserve natural
systems as the basis for life. And biotechnology must be presented more
predominantly in the debates as an integrated form of production that reduces
the farmer’s imprint on the environment. This can be explained in terms of a
legacy for future generations. Biotechnology can be presented as a component
of good stewardship.
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The challenge is to bridge the gap between economic realities in the North
and the aspirations of the billions of people living in developing countries,
largely in the South. Clearly, the first problem to overcome is the communica-
tion gap due to differences in social and political heritage. Organizations that
speak (or claim to speak) for local or indigenous communities, however, are
often merely of the reactionary type with little or no support in those
communities. Such are also the most vocal in international political forums
with the effect of further delaying rapprochement among the systems, i.e. the
establishment, corporations, and local/indigenous communities.
No matter how worthwhile the claimed aspirations of such activist entities
may be, they contribute little in today’s world but polarize the debates. True
change in attitudes does not, and will not, come from the actions of environ-
mental pressure groups nor from multinational conglomerates, but from a
systematic sensitization of the public. This, in turn, will influence policy
makers and corporations alike, and will yield results in the longer term.
The first conclusion from this discussion should be that the issues are
complex, not so much in themselves but because they all meet at one place:
the new technology of biotechnology.
SCIENCE AND HISTORY
Oscar Wilde said, “The one duty we owe to history is to rewrite it.” I say it is
better to make history rather than to rewrite it!
How might we make history in the area of biotechnology and international
development? What institutional arrangements could ensure that benefits are
“equitably” shared among companies and countries and individuals and the
environment? How can we even define “equitable sharing” when equitable
is so much a concept that depends more on the eye of the beholder than
on measurable characteristics? Clearly, we need to bring about shifts in the
perception of values, including prejudices about modern biotechnology.
Perhaps a new type of biotech enterprise, one publicly owned and managed
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like a private enterprise, would allow us to sway public opinion. We certainly
need something big and bold if we are to bring about needed change.
The solution, perhaps, lies in the creation of an entirely new type of
enterprise. We all recognize the exceptional achievements of the CGIAR in the
latter part of the twentieth century, yet I challenge the CGIAR system that it is
no longer appropriate for the twenty-first century. The CGIAR system’s success
was based on the transfer of public technologies, but it has not been able to
“recover” from its successes and adapt to the changing environment in which it
operates. After years of internal debate on the impact of IP and biotechnology,
the CGIAR still does hot have a consistent policy towards either, yet alone a
comprehensive strategy on how to deal with the proprietary nature of the
science on which it relies. The CGIAR operates in a global context, but so far
it has failed to “use” globalization to its own advantage and thus it has failed to
serve the poor most effectively with its dwindling financial and technological
resources.
Yet, with the advent of the life sciences, the potential to improve the human
situation was unprecedented in history. Globalization is enabling the mobiliza-
tion of worldwide science and technology for the betterment of humankind. Yet
the promise is ours only if we manage to deploy improved products to the poor
and wealthy alike. A new vision and initiative is warranted for biotechnology to
produce and deliver its capabilities not only for the most vulnerable billion
people but also the wealthy. The developing world is superbly and uniquely
positioned to translate this vision into reality.
At a seminar at Cornell University in September 1999, I proposed the
creation of a novel, highly efficient and sustainable organization as a model
for the next century, with the potential to exceed many-fold the impact of the
CGIAR and the green revolution of the twentieth century. In short, the vision is
to “sustain globalization in the life sciences” by creating a new form of private/
public partnership with the life science capabilities of a large biotechnology
company as the keystone. Development, both economic and scientific, would
be accelerated through the synergy of private/public energies.
At the centerpiece of the “privic” strategy would be, for example, a large
biotechnology company’s agricultural life sciences division. The science and
technology would be poised to deliver the long-promised benefits of biotech,
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gradually, to the entire world. Meanwhile, the value embedded in other
divisions of the biotech company, including chemicals and seeds, would be
returned to shareholders as these business units of the current enterprise are
spun off.
Financing for the “privic” would come from public (government, multi-
lateral), foundations, and private sources, and from future licensing of its
technologies (to corporations and at a discount to developing countries).
All would benefit from this strategy as the most effective means of sustaining
agricultural and economic advancement, and human well-being.
Market growth would come by expanding biotech into developing-world
markets where the technology is needed most. Current revenue streams would
be maintained and expanded through licensing arrangements with corporations
(current competitors), the CGIAR, universities, and national programs around
the world.
Public opposition to plant biotech would be curbed rapidly as a result of
the display of its startling value for the world’s poorer people, thus realizing
biotech’s promise in the near term.
Research and development would be efficiently expanded by focusing on a
mix of commercial (for licensing) and developing-country needs and priorities.
Human capital would be enhanced by ensuring that researchers in developing
countries would participate in the R&D and would have ready access to
biotech’s tools to solve their national and regional agricultural and nutritional
problems.
The staff, talent, strategies, R&D priorities, and finances of the “privic”
would be managed according to corporate principles by a CEO supported by
an executive and management board. A small non-executive oversight board of
senior people serving in their individual capacities would represent national
and topical interests.
CONCLUSIONS
Only two questions remain. First, is there a better idea on the table to bring
about the change needed to make biotechnology flourish and deliver its
promise to the world’s citizens at large? And if there is no better idea, then
the question is: what is to be done next to make the “privic” work? Seven
simple steps would be needed:
• Seek limited funding for a feasibility study.
• Prepare issues and options briefs (financing the deal, governance,
management, R&D strategy, cash-flow projections, etc.).
• Commission an investment bank’s preliminary assessment of valuation
and financial options.
• Approach the Chairpersons and CEOs of the other major agricultural
biotechnology companies.
• Organize a “retreat”-type meeting with senior people and advisers to:
— determine feasibility, refine concept, and set policy and implementation
strategy,
— elaborate specific areas for further investigation/determination and
allocate follow-up tasks, and
— identify members for a formal steering committee.
• Convene the formal steering committee meeting to implement strategy.
• Launch the “privic.”
It could all be done in 9 months, or perhaps even less. Because biotechnology
is at the heart of the long-term sustainability of our environment, because
biotechnology is at the heart of our survival in the long term, it represents an
opportunity today to forge new partnerships for tomorrow.
Q: As you mentioned, the green revolution resulted from research at CGIAR
institutes in the Philippines and Mexico. I happen to know that biotechnology
research is in progress at the International Institute of Tropical Agriculture in
Nigeria and at the International Rice Research Institute in the Philippines, and,
I assume that significant effort is being expended in biotechnology at the other
international institutes. Please elaborate on that, and address the question: to
what extent is it possible for the international institutes to make a significant
contribution to increasing food production in developing countries, using the
tool of biotechnology, without any involvement of industry?
A: Intellectual property rights are often blamed as a stumbling block, but I
think that reveals a lack of understanding of IP and patents. The annual budget
for the CGIAR centers, CIMMYT in Mexico, IITA in Nigeria, IRRI in the
Philippines, CIAT in Colombia, etc. is about $310 million, of which $28 million
are spent on biotechnology. A few years ago, the R&D budget of a typical
company like Novartis may have been three to four times that amount for
agricultural biotechnology alone. Based on published data, private investment
in biotechnology in agriculture is approximately $1.1 billion, whereas the entire
developing world spends just over $100 million, of which most goes into
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capacity building and not into product development. So, the CGIAR system
is not in a position to develop major biotechnology applications for the
developing world. It can best do so by forging stronger alliances with the
private sector. But progress in this has been very slow because, for the past
seven or eight years, the CGIAR has been debating what their policy should be
on biotechnology, so far without resolution. The reason is that, around the table
are funding donors, bilateral agencies, representatives of developing countries,
environmental pressure groups, and companies, all with conflicting agendas.
It seems impossible for such an institution to elucidate a clear vision, which is
very regrettable. The green revolution was successful because relatively few
individuals were involved, Norman Borlaug among others. I think it is possible
for the CGIAR to contribute a great deal, but not within the strictures of its
current governance. That is why new institutions are needed, possibly as
brokers or go-betweens, with dramatic new approaches, such as the develop-
ment of the “privic” concept.
